IBA Launches Cyclone® iKure for Industrial-Scale Astatine-211 Production
Event summary
- IBA launched Cyclone® iKure, a cyclotron designed for industrial-scale Astatine-211 (At-211) production, on June 1, 2026.
- The system is engineered for high-yield At-211 output, automated processes, and compact footprint to reduce infrastructure costs.
- IBA aims to address the production challenge of At-211, a key isotope for targeted alpha therapy in precision oncology.
- The launch extends IBA’s cyclotron portfolio from diagnostic imaging to therapeutic alpha-isotope production.
The big picture
IBA’s launch of Cyclone® iKure positions the company at the forefront of targeted alpha therapy, a rapidly evolving field in precision oncology. By addressing the production challenges of At-211, IBA aims to accelerate the transition of At-211-labeled drugs from early-stage programs to routine clinical application. The company’s strategic partnerships and ecosystem leadership further reinforce its commitment to building a complete European At-211 value chain.
What we're watching
- Market Adoption
- The pace at which Cyclone® iKure will be adopted by radiopharmaceutical manufacturers and healthcare providers.
- Regulatory Compliance
- Whether Cyclone® iKure will meet applicable CE marking requirements and other regulatory standards.
- Strategic Partnerships
- How IBA’s partnership with Framatome will impact the transatlantic At-211 production network.
Related topics